Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial.
Musinguzi A, Kasidi JR, Kadota JL, Welishe F, Nakitende A, Akello L, Nakimuli J, Kunihira LT, Opira B, Baik Y, Patel D, Sammann A, Berger CA, Aschmann HE, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC, Katahoire AR. Musinguzi A, et al. Among authors: welishe f. PLOS Glob Public Health. 2024 Oct 24;4(10):e0003347. doi: 10.1371/journal.pgph.0003347. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39446746 Free PMC article.
Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial.
Musinguzi A, Kasidi JR, Kadota JL, Welishe F, Nakitende A, Akello L, Nakimuli J, Kunihira LT, Opira B, Baik Y, Patel D, Sammann A, Berger CA, Aschmann HE, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC, Katahoire AR. Musinguzi A, et al. Among authors: welishe f. medRxiv [Preprint]. 2024 Aug 22:2024.08.19.24308041. doi: 10.1101/2024.08.19.24308041. medRxiv. 2024. Update in: PLOS Glob Public Health. 2024 Oct 24;4(10):e0003347. doi: 10.1371/journal.pgph.0003347. PMID: 39314926 Free PMC article. Updated. Preprint.
Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda.
Kadota JL, Musinguzi A, Aschmann HE, Akello L, Welishe F, Nakimuli J, Berger CA, Kiwanuka N, Phillips PP, Katamba A, Dowdy DW, Cattamanchi A, Semitala FC. Kadota JL, et al. Among authors: welishe f. medRxiv [Preprint]. 2024 Aug 9:2024.08.08.24311632. doi: 10.1101/2024.08.08.24311632. medRxiv. 2024. PMID: 39148841 Free PMC article. Preprint.
Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda.
Musinguzi A, Aschmann HE, Kadota JL, Nakimuli J, Welishe F, Kakeeto J, Namale C, Akello L, Nakitende A, Berger C, Katamba A, Tumuhamye J, Kiwanuka N, Dowdy DW, Cattamanchi A, Semitala FC. Musinguzi A, et al. Among authors: welishe f. IJTLD Open. 2024 Feb 1;1(2):83-89. doi: 10.5588/ijtldopen.23.0283. eCollection 2024 Feb. IJTLD Open. 2024. PMID: 38966690 Free PMC article.
Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Semitala FC, et al. Among authors: welishe f. PLoS Med. 2024 Feb 20;21(2):e1004356. doi: 10.1371/journal.pmed.1004356. eCollection 2024 Feb. PLoS Med. 2024. PMID: 38377166 Free PMC article. Clinical Trial.
Preferences of people living with HIV for features of tuberculosis preventive treatment regimens - a discrete choice experiment.
Aschmann HE, Musinguzi A, Kadota JL, Namale C, Kakeeto J, Nakimuli J, Akello L, Welishe F, Nakitende A, Berger C, Dowdy DW, Cattamanchi A, Semitala FC, Kerkhoff AD. Aschmann HE, et al. Among authors: welishe f. medRxiv [Preprint]. 2023 Sep 14:2023.09.13.23295043. doi: 10.1101/2023.09.13.23295043. medRxiv. 2023. PMID: 37745521 Free PMC article. Preprint.
Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
Sung J, Musinguzi A, Kadota JL, Baik Y, Nabunje J, Welishe F, Bishop O, Berger CA, Katahoire A, Nakitende A, Nakimuli J, Akello L, Kasidi JR, Kunihira Tinka L, Kamya MR, Sohn H, Kiwanuka N, Katamba A, Cattamanchi A, Dowdy DW, Semitala FC. Sung J, et al. Among authors: welishe f. Int J Tuberc Lung Dis. 2023 Jun 1;27(6):458-464. doi: 10.5588/ijtld.22.0679. Int J Tuberc Lung Dis. 2023. PMID: 37231600 Free PMC article.
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Semitala FC, et al. Among authors: welishe f. PLoS Med. 2021 Dec 16;18(12):e1003875. doi: 10.1371/journal.pmed.1003875. eCollection 2021 Dec. PLoS Med. 2021. PMID: 34914696 Free PMC article. Clinical Trial.
Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.
Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, Berger CA, Katamba A, Kiwanuka N, Kamya MR, Dowdy D, Cattamanchi A, Katahoire AR. Semitala FC, et al. Among authors: welishe f. Implement Sci Commun. 2021 Jun 30;2(1):71. doi: 10.1186/s43058-021-00173-2. Implement Sci Commun. 2021. PMID: 34193311 Free PMC article.
Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Kadota JL, et al. Among authors: welishe f. Implement Sci. 2020 Aug 12;15(1):65. doi: 10.1186/s13012-020-01025-8. Implement Sci. 2020. PMID: 32787925 Free PMC article.
11 results